Setup Form for NIH SBIR



For assistance or further information regarding Foresight's TNA™, please contact Heidi Meisenkothen at 401-273-4844 ext. 21. Email setup form to Ryan Hill at Ryan.Hill@foresightst.com or fax to 401-273-4744.

Foresight ID Number:

1 of esignt 1D Number.	
Company Information: Name, Address, Website	
Contact Person for Guidance, Receipt of Report, and Approval of our Work: Name, Title, Email and Phone	
Primary Technical Contact Person, if Different: Name, Title, Email and Phone	
Name of Technology or Project:	
Your SBIR Award Grant/Contract Number:	
Non-Proprietary Description of Technology: This is the only information that we disclose to experts, end-users and potential commercialization partners. In order to get the most informative feedback from these individuals, the more information that is included in this description the better.	
 Typically, the non-proprietary description is 1-2 paragraphs in length. In addition to the technology description, the following information, if available, in a non-proprietary format, may be considered for inclusion in this section: Brief overview of technology and the problem it aims to solve; Relative size of technology (i.e., Is it bigger than a breadbox? Can it fit on a crowded lab bench?); Stage of technology's maturity (i.e., Conceptual stages? <i>In vitro</i>, pre-clinical or clinical validation studies performed? Do you have a prototype?). 	

Confidential Page 1

Setup Form for NIH SBIR

Comparison with Substitutes: What are the major substitutes for your technology? Why is your technology better than these alternatives? Please be as specific as possible.	
Do you have a primary application of interest? Your best guess as to where you want your technology commercialized.	
What other applications have you considered?	
Do you have a patent or have you published anything on this technology: If yes, please list patent number(s) and/or most relevant publications.	
Geographic Region of Interest: Note - all reports will default to 'global' unless a regional focus is specified.	
Are there any companies or people we SHOULD NOT contact?	
We normally identify your company or organization when speaking to people. <i>Do you wish to remain anonymous?</i>	
Please provide key words to describe this project.	

Indicate by 'X'	SBIR Phase II submission dates *	EARLIEST POSSIBLE START DATE	ESTIMATED GROUP COMPLETION DATE
	December 5 2011	September 2011	November 2011
	April 5 2012	November 2011	March 2012

*NOTE: If applicable, indicate your preference based on if or when you plan to submit a Phase II SBIR application. If you do not plan to submit a Phase II application in the dates indicated above or do not have a preference, leave the first column blank. NIH will do its best to accommodate any preferences.

Confidential Page 2